Skip to content

Author

Jacob Sands

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group–American College of Radiology Imaging Network E4512): a phase 3 trial

It is suggested that crizotinib should not be recommended as an adjuvant therapy for patients with resected, early-stage ALK-positive NSCLC and that crizotinib should not be recommended as an adjuvant therapy for patients with resected ALK-positive NSCLC.

D. E. Gerber, Yating Wang, C. Langer et al. · 2 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.